Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE · Healthcare

₹1,197.90+0.41%06 Nov 2026

Ask the data

Instant answers about Zydus Lifesciences Ltd. — computed from its filings, no language model

Market cap₹1,19,550 cr

Current price₹1,197.90

High / Low₹1,246 / ₹861

P/E28.6

P/B4.30

Book value₹278.7

ROE15.0%

ROCE15.0%

Debt / equity0.48

Dividend yield0.93%

EPS (TTM)₹41.88

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	11,936	13,166	14,253	15,102	15,265	17,237	19,547	23,242	27,148
EBITDA	2,848	2,973	2,783	3,341	3,341	3,860	5,384	7,058	8,475
Operating margin	23.9%	22.6%	19.5%	22.1%	21.9%	22.4%	27.5%	30.4%	31.2%
Interest	91	194	342	164	127	130	81	166	439
Depreciation	539	599	696	725	713	723	764	916	1,408
Profit before tax	2,331	2,382	1,495	2,285	2,838	2,590	4,809	6,027	6,621
Tax	564	530	320	147	512	588	978	1,412	1,595
Net profit	1,776	1,849	1,177	2,134	4,487	1,960	113	147	5,040
EPS ₹	17.35	18.06	11.49	20.84	43.84	19.30	38.14	44.97	50.09
Operating cash flow	—	—	—	—	2,078	2,689	3,228	6,777	2,117
Capex	—	—	—	—	1,203	1,031	907	1,713	3,394
Dividend paid	—	—	—	—	372	267	621	302	1,106
Total assets	18,065	23,483	23,687	23,885	—	25,756	29,281	37,202	52,407
Equity	8,744	10,386	10,376	12,992	—	17,516	19,830	23,953	27,111

Quarterly performance

last 35 quarters · ₹ crore

showing latest 8 of 35 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	3,250	2,894	2,961	3,578	3,733	3,496	3,367	3,638	3,752	3,640	3,820	3,796	3,847	4,025	3,785	3,655	3,864	4,073	4,135	4,362	5,011	5,140	4,369	4,505	5,534	6,208	5,237	5,269	6,528	6,574	6,123	6,864	7,587	8,017	7,910
Operating profit	870	645	688	840	800	632	626	693	791	815	863	807	855	933	861	752	718	833	815	956	1,256	1,505	1,146	1,102	1,630	2,084	1,461	1,388	2,126	2,088	2,016	1,816	2,554	1,929	1,894
Operating margin	26.8%	22.3%	23.2%	23.5%	21.4%	18.1%	18.6%	19.1%	21.1%	22.4%	22.6%	21.3%	22.2%	23.2%	22.7%	20.6%	18.6%	20.5%	19.7%	21.9%	25.1%	29.3%	26.2%	24.5%	29.5%	33.6%	27.9%	26.3%	32.6%	31.8%	32.9%	26.5%	33.7%	24.1%	24.0%
Other income	29	101	30	31	38	23	27	20	44	22	28	28	-40	32	53	61	79	66	44	38	38	36	54	38	156	63	68	58	81	155	109	111	134	106	130
Interest	15	35	36	46	77	89	90	80	82	68	46	27	23	27	30	31	38	34	35	33	28	18	9	20	35	32	25	32	77	85	101	130	123	156	187
Depreciation	144	142	148	154	156	172	172	174	178	177	179	180	189	183	185	183	185	181	182	182	179	180	184	195	205	215	234	229	238	238	302	360	508	555	604
Profit before tax	740	570	535	672	606	394	122	457	522	593	534	627	530	755	604	599	573	681	643	780	486	1,329	1,007	926	1,547	1,900	1,271	1,184	1,672	1,921	1,687	1,353	1,660	1,307	1,234
Tax	144	120	125	159	127	79	40	93	108	124	111	115	-202	142	100	111	109	118	137	195	137	216	226	214	321	436	373	180	423	434	454	388	318	354	334
Net profit	591	460	418	511	460	304	107	374	392	454	473	527	679	587	3,002	500	397	518	522	623	297	1,087	801	790	64	1,420	911	1,024	73	1,467	1,259	1,042	1,272	940	926
EPS ₹	5.77	4.50	4.08	4.99	4.49	2.97	1.05	3.65	3.83	4.43	4.62	5.15	6.63	5.74	29.32	4.89	3.88	5.06	5.15	6.15	2.93	10.74	7.91	7.80	11.69	14.11	9.06	10.17	11.64	14.58	12.51	10.36	12.65	9.35	9.28
Revenue YoY	—	—	—	—	14.8%	20.8%	13.7%	1.7%	0.5%	4.1%	13.5%	4.3%	2.5%	10.6%	-0.9%	-3.7%	0.4%	1.2%	9.2%	19.4%	29.7%	26.2%	5.7%	3.3%	10.4%	20.8%	19.9%	17.0%	18.0%	5.9%	16.9%	30.3%	16.2%	22.0%	29.2%
Profit YoY	—	—	—	—	-22.1%	-34.1%	-74.3%	-26.8%	-14.8%	49.5%	341.6%	41.0%	73.3%	29.3%	534.2%	-5.1%	-41.5%	-11.7%	-82.6%	24.5%	-25.4%	109.7%	53.2%	26.8%	-78.5%	30.6%	13.8%	29.6%	14.1%	3.3%	38.1%	1.8%	1647.9%	-35.9%	-26.5%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Zydus Lifesciences Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	1,944	2,425	2,920	3,151	3,352	3,952	5,284	7,035	4,347
Operating profit	420	610	708	668	605	777	1,534	2,543	508
Operating margin	21.6%	25.2%	24.2%	21.2%	18.0%	19.7%	29.0%	36.1%	11.7%
Other income	54	44	58	239	81	307	185	134	584
Interest	76	45	32	128	104	42	43	22	19
Depreciation	83	90	97	108	114	127	212	221	256
Profit before tax	296	520	637	670	469	914	1,465	2,434	817
Tax	30	17	27	13	2	31	194	456	18
Net profit	266	503	610	658	467	883	1,271	1,977	799

Quarters

showing latest 8 of 42 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	447	439	403	482	540	434	488	596	644	613	572	783	739	702	696	782	771	815	784	819	795	784	954	838	985	1,027	1,102	1,113	1,253	1,465	1,454	1,915	1,934	1,757	1,429	1,272	1,118	1,129	828	1,055	1,738	1,574
Operating profit	102	90	67	90	120	106	103	160	153	150	147	240	199	168	101	190	159	136	182	191	95	81	238	146	170	186	275	264	324	483	463	719	762	610	452	234	121	85	68	198	650	409
Operating margin	22.8%	20.5%	16.6%	18.7%	22.3%	24.5%	21.2%	26.8%	23.7%	24.5%	25.8%	30.7%	26.9%	23.9%	14.5%	24.4%	20.7%	16.8%	23.2%	23.3%	12.0%	10.3%	24.9%	17.4%	17.3%	18.1%	25.0%	23.7%	25.9%	33.0%	31.8%	37.5%	39.4%	34.7%	31.6%	18.4%	10.8%	7.5%	8.3%	18.8%	37.4%	26.0%
Other income	6	15	8	10	11	24	9	13	11	11	8	16	24	16	2	9	154	64	12	3	52	15	11	218	9	60	20	16	144	10	15	15	42	18	58	44	84	52	405	52	67	58
Interest	7	9	13	20	5	16	33	15	11	10	8	14	7	7	3	7	60	44	17	27	28	30	19	15	10	8	10	8	10	10	14	7	7	6	2	6	6	4	4	12	24	3
Depreciation	18	18	19	19	19	21	23	21	22	22	25	24	23	25	25	25	28	27	29	28	27	31	28	30	32	32	32	53	52	51	55	52	54	55	60	65	67	70	54	66	70	78
Profit before tax	81	75	42	61	106	87	43	136	131	130	123	218	192	152	76	167	226	130	148	139	93	34	202	319	136	206	253	219	405	432	409	674	743	568	449	207	132	63	415	172	623	387
Tax	10	12	7	5	10	14	0	14	6	5	-8	19	10	12	-14	14	-5	-5	8	6	-5	0	-0	-1	-16	11	36	22	40	71	62	119	128	98	111	42	23	10	-57	81	173	80
Net profit	71	63	35	56	96	72	43	123	124	125	131	199	182	140	90	153	231	134	139	133	97	34	203	320	152	195	217	197	366	361	347	556	614	470	338	165	109	54	471	91	450	306
EPS ₹	5.68	5.02	2.82	4.43	7.60	5.29	3.12	8.98	9.11	9.18	9.60	9.70	8.87	6.86	4.38	7.47	11.28	6.55	6.81	6.48	4.76	1.66	9.89	15.61	7.41	9.52	10.58	9.64	17.86	17.64	16.95	27.14	29.99	4.59	3.30	1.61	1.06	0.53	4.61	0.89	4.39	2.99
Revenue YoY	—	—	—	—	20.6%	-1.0%	21.0%	23.6%	19.3%	41.2%	17.2%	31.5%	14.8%	14.4%	21.6%	-0.2%	4.3%	16.1%	12.7%	4.8%	3.2%	-3.7%	21.7%	2.3%	23.9%	31.0%	15.5%	32.8%	27.2%	42.6%	32.0%	72.1%	54.4%	19.9%	-1.7%	-33.6%	-42.2%	-35.8%	-42.0%	-17.0%	55.4%	39.4%
Profit YoY	—	—	—	—	33.9%	14.5%	20.3%	120.3%	30.3%	73.5%	207.7%	62.1%	46.0%	12.0%	-31.5%	-23.0%	27.2%	-4.4%	55.3%	-13.2%	-57.8%	-74.7%	45.3%	140.9%	55.7%	474.0%	7.0%	-38.3%	140.9%	85.3%	60.2%	181.7%	68.0%	30.0%	-2.6%	-70.3%	-82.2%	-88.5%	39.5%	-44.6%	312.7%	468.5%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 32 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	22.6%	17.8%	16.3%	13.3%	12.0%	11.3%	12.8%	16.3%	17.8%	16.4%	17.4%	36.9%	36.7%	34.5%	34.0%	11.6%	12.4%	11.2%	14.4%	15.0%	15.9%	13.8%	15.5%	14.6%	15.7%	14.3%	14.5%	15.1%	15.2%	18.6%	16.6%	15.0%
ROCE	19.1%	14.7%	14.0%	12.0%	10.9%	10.5%	11.6%	13.7%	14.4%	14.7%	15.4%	15.7%	15.6%	15.9%	15.5%	13.8%	14.8%	14.6%	17.9%	19.5%	20.2%	23.7%	26.6%	26.2%	27.4%	22.8%	23.1%	19.4%	20.1%	18.2%	16.8%	15.0%
Net margin	15.6%	14.0%	12.3%	9.7%	8.7%	8.3%	9.2%	11.4%	12.3%	14.1%	14.6%	31.0%	31.1%	29.3%	28.7%	12.3%	12.5%	11.2%	13.6%	14.9%	15.6%	14.0%	14.9%	14.8%	15.4%	14.7%	14.7%	15.6%	14.7%	18.6%	15.8%	13.8%
EBITDA margin	24.0%	22.6%	21.5%	20.4%	19.3%	19.2%	20.3%	21.3%	21.8%	22.1%	22.3%	22.4%	22.2%	21.3%	20.6%	19.8%	20.2%	22.0%	24.3%	25.8%	26.3%	27.5%	28.9%	29.2%	29.5%	30.4%	29.9%	31.1%	30.8%	31.2%	29.1%	27.0%
Debt / equity	0.58	0.69	0.69	0.69	0.69	0.68	0.68	0.68	0.68	0.28	0.28	0.28	0.28	0.28	0.28	0.15	0.15	0.07	0.07	0.01	0.01	0.04	0.04	0.01	0.01	0.13	0.13	0.38	0.38	0.43	0.43	0.48
Interest coverage	20.12	13.31	9.91	6.95	5.69	5.38	6.29	8.62	11.22	14.97	20.87	24.40	23.25	20.92	19.33	18.95	20.02	20.94	29.48	42.26	51.44	60.22	57.45	51.52	48.63	37.33	28.69	22.94	17.90	16.09	12.77	10.32
Asset turnover	0.70	0.56	0.59	0.60	0.61	0.60	0.61	0.63	0.63	0.63	0.65	0.65	0.64	0.64	0.64	0.61	0.64	0.68	0.72	0.73	0.74	0.67	0.70	0.68	0.71	0.62	0.63	0.52	0.56	0.52	0.55	0.55

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 17 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	102	102	102	102	102	102	102	102	101	101	101	101	101	101	101	101	100
Other equity / reserves	3,192	3,980	5,597	6,858	8,642	10,284	10,273	12,890	16,564	17,415	18,632	19,729	21,724	23,852	25,201	27,011	27,718
Total equity	3,295	4,083	5,699	6,960	8,744	10,386	10,376	12,992	16,665	17,516	18,733	19,830	21,825	23,953	25,302	27,111	27,817
Borrowings	2,265	2,334	2,107	4,945	5,113	7,147	7,041	3,680	2,419	1,163	150	769	150	3,170	9,594	11,770	13,250
Current liabilities	2,814	3,285	3,461	5,306	6,072	7,342	8,269	7,861	6,114	5,527	4,358	5,340	5,349	9,042	9,448	15,712	18,024
Non-current liabilities	1,589	1,342	1,255	2,799	3,047	4,461	3,707	1,094	741	537	576	1,837	1,940	1,802	9,360	7,112	7,261
Total assets	7,986	9,047	10,551	15,221	18,065	23,483	23,687	23,885	25,629	25,756	25,879	29,281	31,446	37,202	46,897	52,407	55,607
Property, plant & equipment	2,158	2,418	2,607	3,290	3,819	5,106	5,452	5,550	5,764	5,696	5,717	5,803	6,102	6,042	7,099	9,231	9,276
Capital work-in-progress	892	798	951	1,543	1,527	837	742	783	958	1,130	1,220	1,112	1,051	1,318	1,190	1,166	1,636
Investments	87	154	416	435	746	674	765	830	1,087	1,547	1,675	1,220	2,596	6,408	5,878	7,540	8,348
Inventories	1,368	1,536	1,337	1,804	2,385	2,688	2,789	3,236	3,405	3,413	3,304	3,442	3,717	3,944	4,750	5,628	6,882
Receivables	1,134	1,588	1,747	2,278	3,206	3,951	3,663	3,127	3,725	4,417	3,915	5,220	4,670	4,025	4,963	5,416	4,381
Cash & equivalents	549	670	639	1,544	537	421	845	665	455	488	346	413	1,061	827	882	855	669

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 6 periods

	FY15‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	994	2,078	2,689	3,228	6,777	2,117
Cash from investing	-465	1,154	1,171	-1,475	-8,372	-8,296
Cash from financing	-351	-868	-4,400	-1,804	2,031	5,997
Capex	512	1,203	1,031	907	1,713	3,394
Free cash flow	481	876	1,658	2,321	5,064	-1,277
Dividends paid	184	372	267	621	302	1,106

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹9,276 cr17%

CWIP

₹1,636 cr3%

Investments

₹8,348 cr15%

Inventories

₹6,882 cr12%

Receivables

₹4,381 cr8%

Cash & equivalents

₹669 cr1%

Other assets

₹24,415 cr44%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%

StoxGud checklist: Bullish setup · 10/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+3.9%

6 months+27.4%

1 year+19.4%

3Y CAGR+27.0%

5Y CAGR+19.4%

10Y CAGR+12.1%

50-day avg₹1,157.52

200-day avg₹1,040.66

RSI (14)67

Long-term financials (FY12–FY16)

from published annual reports

Year	Revenue	Profit before tax	Net profit
FY16	₹9,838 Cr	₹2,126 Cr	₹1,553 Cr
FY15	₹8,651 Cr	₹1,446 Cr	₹38 Cr
FY14	₹7,224 Cr	₹959 Cr	₹836 Cr
FY13	₹6,358 Cr	₹809 Cr	₹690 Cr
FY12	₹5,263 Cr	₹794 Cr	₹681 Cr

Years before FY17 follow the older Indian GAAP standard, so they are not exactly comparable with recent years.

Compare Zydus Lifesciences Ltd. with

Torrent Pharmaceuticals vs Zydus Lifesciences Laurus Labs vs Zydus Lifesciences Apollo Hospitals Enterprise vs Zydus Lifesciences Zydus Lifesciences vs Dr. Reddy's Laboratories Zydus Lifesciences vs Cipla Zydus Lifesciences vs Mankind Pharma

FAQs

What is the share price of Zydus Lifesciences Ltd.?

Zydus Lifesciences Ltd. (ZYDUSLIFE) closed at ₹1,197.90 on NSE on 06 Nov 2026.

What is the market cap of Zydus Lifesciences Ltd.?

₹1,19,550 crore at the latest close.

What is the P/E ratio of Zydus Lifesciences Ltd.?

28.6, on trailing-twelve-month earnings from its filings.

How fast is Zydus Lifesciences Ltd. growing?

Zydus Lifesciences Ltd.: revenue has compounded at 16.3% a year over three years; net profit at 37.0% a year. Latest-quarter revenue is up 29.2% year on year, profit down 26.5%.

How profitable is Zydus Lifesciences Ltd.?

On a trailing-twelve-month basis return on equity is 15.0%, return on capital employed 15.0%, operating margin 27.0%, net margin 13.8%.

How much debt does Zydus Lifesciences Ltd. have?

Zydus Lifesciences Ltd. is lightly geared: debt to equity is 0.48 with borrowings of ₹13,250 cr against cash of ₹669 cr (balance sheet of 2026-09-30). Operating profit covers interest 10.3 times.

Financials parsed from Zydus Lifesciences Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.